Introduction
Methods
Trial design and patients
Statistical analyses
Statistical analyses of endpoint by subgroup
Results
Characteristic | IFN β-1a 44 µg (N = 829) | Ocrelizumab 600 mg (N = 827) |
---|---|---|
Age | ||
Years, mean (SD) | 37.2 (9.2) | 37.1 (9.2) |
< 40 years, n (%) | 484 (58.4) | 496 (60.0) |
≥ 40 years, n (%) | 345 (41.6) | 331 (40.0) |
Female, n (%) | 552 (66.6) | 541 (65.4) |
Body mass index | ||
kg/m2, mean (SD) | 26.4 (6.2) | 26.2 (5.8) |
< 25 kg/m2, n (%) | 413 (50.2) | 406 (49.6) |
≥ 25 kg/m2, n (%) | 409 (49.8) | 412 (50.4) |
Time since MS symptom onset, years, mean (SD) | 6.5 (6.1) | 6.7 (6.2) |
Time since RMS diagnosis, years, mean (SD) | 3.9 (4.9) | 4.0 (4.9) |
No DMT in the 2 years before study inclusion, n (%) | 606 (73.4)a,b | 605 (73.3)a,b |
EDSS score | ||
Mean (SD) | 2.8 (1.3)c | 2.8 (1.3) |
< 2.5, n (%) | 329 (39.7)c | 310 (37.5) |
≥ 2.5, n (%) | 499 (60.3)c | 517 (62.5) |
< 4.0, n (%) | 627 (75.7)c | 629 (76.1) |
≥ 4.0, n (%) | 201 (24.3)c | 198 (23.9) |
Number of relapses, mean (SD) | ||
In the last year, mean (SD) | 1.33 (0.69)d | 1.32 (0.67)d |
In the last 2 years, mean (SD) | 1.76 (0.92)d | 1.79 (0.91)d |
≤ 1 relapse, n (%) | 584 (70.6)d | 585 (70.8)d |
≥ 2 relapses, n (%) | 243 (29.4)d | 241 (29.2)d |
MRI | ||
Patients with no T1 gadolinium-enhancing lesions, n (%) | 495 (60.2)e | 485 (59.3)e |
Patients with ≥ 1 T1 gadolinium-enhancing lesion, n (%) | 327 (39.8)e | 333 (40.7)e |
Number of T2 lesions, mean (SD) | 51 (38)f | 50 (39)f |
T2 lesion volume, cm3, mean (SD) | 10.18 (11.8)f | 10.79 (14.1)f |
Normalized brain volume, cm3, mean (SD) | 1500 (89)g | 1502 (88)g |
Normalized brain volume < 1500 cm3, n (%) | 398 (48.7)g | 402 (49.0)g |
Normalized brain volume ≥ 1500 cm3, n (%) | 420 (51.3)g | 418 (51.0)g |